BioCardia, Inc. Form 8-K Summary
Business Context and Reporting Period
BioCardia, Inc. filed a Current Report on Form 8-K dated September 23, 2026. The filing reports an Item 8.01 “Other Events” update concerning the timing of an FDA Helix Pre-Submission and the PMDA CardiAMP HF Shonin Submission.
Financial Metrics and Capital Resources
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing does not provide comparative financial information or quantify changes versus a prior period.
Guidance, Outlook, Risks, and Unusual Items
- BioCardia stated that it issued a September 23, 2026 press release confirming timing and providing an update regarding the FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission.
- The press release is attached as Exhibit 99.1, but its substantive text is not included in the provided filing content. Accordingly, the specific timing, regulatory milestones, outlook, risks, and contingencies are not clear from the available text.
- The information under Item 8.01, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the specific FDA Helix Pre-Submission timing and expected next steps.
- Review the exhibit for details regarding the PMDA CardiAMP HF Shonin Submission, including submission status and anticipated regulatory milestones.
- Assess any forward-looking statements, regulatory dependencies, clinical-development risks, and financing implications described in the press release.
- Confirm that no financial results or liquidity information are presented in this 8-K.